Articles tagged with Inflammatory Disorders
A new study published in BMJ Oncology has found that relatively short-term use of immunosuppressant medications to control inflammatory diseases is not associated with an increased risk of developing cancer. The research included over 10,000 participants and tracked their cancer incidence for an average of 10 years.
A new study projects nearly 1 billion people will be living with osteoarthritis, the most common form of arthritis, by 2050. Currently, 15% of individuals aged 30 and older experience osteoarthritis, with obesity being a major risk factor.
Scientists have identified a molecule that regulates nerve cell sensors, which could lead to new therapeutics for obesity, osteoporosis, and inflammatory diseases. The molecule can be modified into peptide-based therapeutics to boost the activity of channels involved in bone strength and satiety.
Researchers discovered that red blood cell particles can reduce fat deposition in arteries by inducing multiple changes in macrophages, including decreased inflammation and increased protection against oxidative damage. This finding offers potential new methods for treating atherosclerosis.
A study found that border-associated macrophages play a crucial role in neuroinflammation and neurodegeneration in Parkinson's disease. Deleting MHCII from these cells reduced neuroinflammation, suggesting they are essential for presenting alpha-synuclein antigens to T cells.
A large study found that fully vaccinated individuals have lower concentrations of inflammatory markers than unvaccinated participants after symptomatic COVID-19 infection. This suggests that vaccination significantly reduces morbidity and mortality by reducing elevated levels of cytokines and chemokines.
Researchers at UC Riverside discovered that female mice secrete more RELMalpha, an immune protein, which protects them against obesity and inflammation. In contrast, male mice have lower levels of RELMalpha, leading to increased inflammation and obesity.
A German research team has successfully developed a novel NMR technique to quantify acute-phase proteins in human serum, which can serve as markers for inflammatory diseases. The study found significant changes in specific acute-phase proteins in patients with COVID-19 or cardiogenic shock, and offers a diagnostic potential.
A groundbreaking study has uncovered potential treatments for inflammatory disorders by targeting specific receptors involved in the immune response. Researchers created mimetic peptides that successfully reduced inflammation in human immune cells and provided significant protection against toxic shock in mice.
Researchers from St. Jude Children's Research Hospital discovered NLRP12 to be the key molecule responsible for inducing inflammatory cell death and pathology in response to heme combined with other cellular damage or infection. This finding provides a new potential drug target to prevent morbidity in certain illnesses.
Researchers found variability in IgA levels between blood and gut samples, suggesting IgA regulates commensal microbes to prevent immune dysregulation. Patients with normal fecal IgA were less likely to develop symptoms, while those deficient in both blood and fecal IgA showed elevated inflammatory cytokines.
Researchers at USP in Brazil discovered that Leishmania parasites manipulate the protein gasdermin-D to prevent the immune system from killing them. This allows the parasite to continue replicating and causing disease. The findings offer hope for developing novel treatments for leishmaniasis, a disease affecting 30,000 people annually.
Researchers found that apoE4 poorly binds factor H, a regulatory factor of immunity, leading to amyloid-β oligomerization and neuroinflammation. This could be a potential solution to preventing Alzheimer's disease, with further research needed to find a bridging molecule.
Scientists at Duke-NUS Medical School have discovered a protein called ASC2 that inhibits inflammasomes, thereby limiting inflammation in bats. This discovery could lead to the development of new anti-inflammatory drugs for human diseases, including those caused by viral infections and ageing.
Researchers at Mount Sinai have discovered a previously unknown way in which the brain and immune system interact in multiple sclerosis. They found that the inflammatory protein interleukin-3 (IL-3) coordinates this communication, inciting the recruitment of immune cells to the brain and exacerbating brain inflammation.
Researchers found that IL-6 signaling in allergen-specific T cells was needed to suppress commitment to the harmful Th2 lineage. SOCS3 upregulation by IL-6 inhibits JAK/STAT internal signaling pathway, preventing Th2 cell priming.
Researchers created a promising injectable cell therapy that reduces inflammation and regenerates articular cartilage in osteoarthritis patients. The treatment was tested in a pre-clinical model and showed ability to reverse cartilage damage and diminish inflammation.
Researchers at Cedars-Sinai Medical Center identified a genetic variant associated with increased risk of developing perianal Crohn's disease, a debilitating manifestation of Crohn's disease. The study highlights the importance of targeting the alternative complement pathway and Complement Factor B (CFB) in treating this condition.
Studies investigate multimorbidity, which is increasing due to improved survival from chronic diseases and population aging. The prevalence of multimorbidity varies greatly depending on the number and types of conditions considered, with some combinations spending more than the sum of individual diseases.
Researchers used transcranial stimulation to regulate Autonomic Nervous System responses and increase oxygen saturation in hospitalized patients with Covid-19. The treatment improved ANS regulation and reduced symptoms without adverse effects.
Researchers from the University of North Carolina Health Care announce that patients receiving anti-TNF biologic treatments combined with methotrexate had better outcomes than those treated with adalimumab alone. The study, published in Gastroenterology, provides clear results that can immediately impact patient care.
A study published in Cell Death & Disease reveals that a protein cross-linking enzyme called TG2 exacerbates kidney fibrosis by polarizing M2 macrophages. The researchers hope to develop treatments for diseases caused by inflammation imbalance, such as fibrosis, cancer, and atherosclerosis.
Researchers at Kyoto University found that neutrophils instruct macrophages to form a bacteria-permissive microenvironment, which could have implications for cancer treatment. The study suggests that A9, an enzyme expressed in neutrophils, may play a key role in this process.
Researchers at Linköping University found that C-reactive protein has a beneficial function in systemic lupus erythematosus, reducing interferon activity and promoting milder disease. The study's findings suggest new treatment strategies to reduce immune complexes and elevated interferon levels.
Researchers at Brigham and Women's Hospital tested a new nasal monoclonal antibody treatment, Foralumab, which decreased inflammatory markers and lung inflammation in patients with COVID-19. The treatment also showed similar effects in multiple sclerosis patients, suggesting its potential use for treating other diseases.
Researchers have found a possible new target for therapies aimed at treating age-related neurological diseases by linking increased presence of immune cells to conditions like Alzheimer's disease. Microglia, specialized immune cells in the brain, can adopt a dysfunctional state that contributes to neurodegenerative diseases.
Researchers at UIC hope to understand how the human immune system regulates lung tissue and develop new treatments for conditions like COPD and pulmonary fibrosis. The grant aims to create an infrastructure for collaboration among researchers studying lung endothelial cells and their role in inflammation.
Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.
A new study from the Keck School of Medicine of USC found that vaping and smoking both cause significant DNA damage in oral epithelial cells. The frequency and duration of vaping were associated with increased levels of DNA damage, which is linked to chronic diseases such as cancer and inflammatory conditions.
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
New UCLA research finds that tobacco smoking and vaping can predispose healthy young people to increased inflammation and severe COVID-19. The study, published in Journal of Molecular Medicine, found higher levels of key proteins in plasma from smokers and vapers compared to non-smokers.
A study published in Science reveals that three faulty genes fail to regulate the immune system's response to SARS-CoV-2, leading to inflammatory overload and multisystem inflammation syndrome in children (MIS-C). The findings provide a mechanistic explanation for Kawasaki disease-like symptoms in these patients.
Salk scientists discovered that when telomeres become very short, they communicate with mitochondria, triggering an inflammatory response. This process destroys cells that could become cancerous, preventing cancer formation. The findings highlight the importance of studying interactions between telomeres, mitochondria, and inflammation.
Macrophages adapt their metabolism according to the organ they reside in, reveals Spanish scientists. This discovery highlights a vulnerability of macrophages that contributes to chronic inflammatory diseases and could be exploited therapeutically for conditions like cardiovascular disease and type 2 diabetes.
A team of biostatisticians created a framework to evaluate the congruence and discordance of laboratory animals with specific human diseases. The tool removes bias from scientific interpretation of animal data for human conditions, revealing that some models mimic biological mechanisms well while others poorly.
Researchers from Nagoya University have identified two microRNAs that are downregulated in systemic lupus erythematosus, a disease where the immune system attacks itself. The study found that these miRNAs regulate the same set of genes through 'seed overlap' co-targeting, which negatively regulates inflammatory cytokine production.
Regulatory T cells suppress self-reactive T cells by controlling protein synthesis, maintaining immune tolerance and preventing autoimmunity. A small molecule inhibitor called RocA also shows promise in mitigating inflammatory responses.
Researchers at NYU Langone Health identified the genetic basis of VEXAS syndrome in 2020, now estimating its prevalence among US men and women over 50. The study found that approximately 1 in 4,269 American men over age 50 and 1 in 26,238 women may develop the syndrome.
A new study finds that andiroba oil accelerates wound healing, increases contraction rates, and promotes local re-epithelialization. The oil also presents a similar potential to low-level laser therapy (LLLT) in treating oral mucositis, a common side effect of chemotherapy.
Researchers analyzed how immunological memory gets generated and maintained to understand its role in cancer and inflammatory diseases. They found that increased inflammation can actually reduce immunological memory, highlighting the need for regulation.
Researchers have isolated two new bacterial species from patients with inflammatory bowel disease (IBD), which break down the protective mucus layer of the gut. The bacteria, Allobaculum mucilyticum and Allobaculum fili, are highly efficient at degrading intestinal mucus, leading to potent immune responses.
A landmark study found a strong genetic correlation between higher education and protective causal association with several gut disorders. The research reveals that better education reduces the risk of diseases such as Alzheimer's and inflammatory bowel disease (IBD).
Researchers at Goethe University Frankfurt have found that jet engine lubrication oils are a significant source of ultrafine particles. These tiny particles can penetrate deep into the lungs and trigger inflammatory reactions, potentially contributing to cardiovascular diseases.
Collagen deposition at injured sites in the gut stimulates cellular reprogramming, converting mature cells into fetal-like cells to generate new tissue. This process has implications for understanding intestinal inflammation and potentially colorectal carcinogenesis.
Research found that common anti-inflammatory drugs taken by children can alter the formation of dental enamel, leading to defects. The study's authors suggest potential harm from widespread use of these medications and plan to conduct a clinical trial to confirm findings in humans.
Researchers found genetic mutations to OAS and RNase L proteins increase inflammatory response in immune cells, leading to MIS-C. This understanding may provide clues to chronic inflammation diseases like Kawasaki disease.
Researchers discovered a modified form of an inflammatory immune protein called complement C3 that is present at higher levels in women's brains with Alzheimer's compared to men's. This finding may explain why women are more likely to develop the disease, as estrogen levels drop during menopause and lose their brain-protective effects.
Salk scientists have developed a new therapeutic compound called FexD, which reverses gut inflammation in mouse models of inflammatory bowel disease. By activating the master regulator protein FXR, FexD reduces inflammation and restores balance to the digestive system.
Researchers identified a genetic variant linked to digestive disturbances in patients with Chagas megaesophagus, a disorder characterized by esophageal dilation and loss of motility. The study suggests that increased interferon-gamma production leads to mitochondrial dysfunction, contributing to the development of the disease.
Researchers at Karolinska Institutet have shown that B cells can prevent intestinal healing by increasing in numbers after bowel damage. The study found that mice lacking B cells recovered more quickly after bowel damage than regular mice.
Researchers found that prednisolone has no effect on improving sense of smell after COVID-19, but patients' sense of smell gradually improves over time. The study suggests that corticosteroids may not be an effective treatment option for persistent olfactory disorders after COVID-19.
A UCF researcher is studying the potential long-term effects of COVID-19 on people with diabetes, including how it can advance their risk for heart disease and other complications. Dr. Singla believes that COVID-19 can alter a person's genetic makeup, leading to enhanced proliferation of disease.
Researchers have discovered how a new class of drugs can inhibit the complement system, which causes damage to the body in some cases. These findings pave the way for further optimization of such inhibitors, potentially leading to novel therapeutic strategies for treating autoimmune diseases.
Researchers from the University of Ottawa found an association between marijuana smoking and chronic damage to airways, including higher rates of paraseptal emphysema and airway inflammatory changes. The study suggests that marijuana smoking may lead to additional lung damage beyond what is seen in tobacco smokers.
Research finds that increased body weight is associated with higher levels of inflammation, signs of gut permeability, and poorer asthma control. The study suggests that targeting the gut could be an effective treatment target for improving asthma control in patients with obesity. Weight loss may also improve symptoms for these patients.
Researchers identified Spns2, an S1P transporter, as a novel drug target for Multiple Sclerosis treatment. Targeting this protein may improve safety profiles and reduce side effects associated with current therapies.
Researchers found histamine releases HMGB1 in vascular endothelial cells, leading to severe symptoms. Administering anti-HMGB1 antibody attenuated hypotension and improved recovery rates.
Researchers have discovered a new role for VWF in regulating immune responses at sites of blood vessel injury, leading to potential treatment options for inflammatory and blood clotting disorders. The study found that VWF plays a key role in repairing damaged blood vessels, which could help prevent heavy bleeding and blood clots.
Researchers have discovered that mutations in mitochondrial-related genes can trigger hyperinflammation, leading to diseases such as Crohn's disease and tuberculosis. The study found that these mutations lead to a new type of cell death called necroptosis, which causes an aggressive inflammatory immune response.
Researchers at UVA Children's will use a sophisticated computer model to better understand and treat Crohn's disease, which can have lifelong consequences for young patients. The team hopes to identify biological markers or metabolic signatures that can be used for early diagnosis and personalized medicine.